Home Newsfeeds Oppenheimer Downgrades AppHarvest to Perform

Oppenheimer Downgrades AppHarvest to Perform

Oppenheimer analyst Kristen Owen downgrades AppHarvest (NASDAQ:APPH) from Outperform to Perform.

byBenzinga Newsdesk

December 2, 2022

1 minute read

Oppenheimer analyst Kristen Owen downgrades AppHarvest (NASDAQ:APPH) from Outperform to Perform.

News

Himax to Integrate WiseEye Ultralow Power AI Sensing Solution with Nvidia TAO to Advance AI Vision Deployment for Enterprises, Battery Powered Devices

By Benzinga Newsdesk

June 3, 4:05 AM

Himax Technologies, Inc. (NASDAQ:HIMX) ("Himax" or "Company"), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today announced it is integrating its

HIMX

Morgan Stanley Maintains Equal-Weight on United Rentals, Raises Price Target to $404

By Benzinga Newsdesk

December 14, 12:52 PM

Morgan Stanley analyst Courtney Yakavonis maintains United Rentals (NYSE:URI) with a Equal-Weight and raises the price target from $320 to $404.

URI

Analyst Applauds Automatic Data Processing Strong Fundamentals, But Keeps An Eye On Macro Headwinds

By Lekha Gupta

September 5, 3:09 PM

RBC Capital Markets analyst Ashish Sabadra initiated coverage on Automatic Data Processing Inc (NASDAQ: ADP) at Sector Perform with a

ADP

Pardes Biosciences Q4 EPS $(0.41) Beats $(0.50) Estimate

By Benzinga Newsdesk

March 14, 4:13 PM

Pardes Biosciences (NASDAQ:PRDS) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.50) by 18 percent. This is a 26.79 percent increase over losses of $(0.56) per share from

PRDS

Oppenheimer Downgrades AppHarvest to Perform

Related Posts

Himax to Integrate WiseEye Ultralow Power AI Sensing Solution with Nvidia TAO to Advance AI Vision Deployment for Enterprises, Battery Powered Devices

Morgan Stanley Maintains Equal-Weight on United Rentals, Raises Price Target to $404

Analyst Applauds Automatic Data Processing Strong Fundamentals, But Keeps An Eye On Macro Headwinds

Pardes Biosciences Q4 EPS $(0.41) Beats $(0.50) Estimate